Welcome to our dedicated page for Mallinckrodt plc news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on Mallinckrodt plc stock.
Mallinckrodt plc (MNK) delivers specialty pharmaceutical solutions and medical imaging innovations across autoimmune, rare disease, and diagnostic markets. This news hub provides investors and healthcare professionals with essential updates on the company’s strategic developments and regulatory milestones.
Access timely reports on earnings announcements, product approvals, research advancements, and partnership agreements. Our curated collection features official press releases alongside verified third-party coverage of MNK’s activities in specialty generics, contrast media production, and therapeutic pipeline progress.
Key content categories include financial performance updates, manufacturing capacity expansions, intellectual property developments, and compliance-related communications. Track MNK’s progress in neurology, rheumatology, and nephrology treatment innovations through objective reporting of material events.
Bookmark this page for streamlined monitoring of Mallinckrodt’s operational updates and market positioning. Check back regularly for authoritative coverage of this specialty pharma leader’s initiatives in addressing complex healthcare challenges through advanced biopharmaceutical solutions.
Mallinckrodt plc announced the availability of Acthar Gel Single-Dose Pre-filled SelfJect Injector in the U.S., offering a new administration option for patients with chronic and acute inflammatory and autoimmune conditions. Key points:
- SelfJect is the first and only ACTH product available in a self-injection device
- FDA approved the supplemental New Drug Application in February 2024
- Available in 40 USP units/0.5 mL and 80 USP units/1.0 mL versions
- Designed for subcutaneous administration by adults 18 years or older
- Simplifies injection process with fewer materials and steps
- Includes safety features like a hidden needle to prevent needlesticks
- Acthar Gel is accessible to over 220 million individuals covered by insurance
- Prescribed by over 9,200 healthcare professionals and used by more than 43,500 patients (2013-2021)
Mallinckrodt plc has agreed to sell its Therakos business to CVC Capital Partners for $925 million. This strategic move aims to optimize Mallinckrodt's capital structure and focus on core areas of expertise. The company plans to use the net proceeds to reduce its net debt by more than 50%. Therakos, a fully integrated extracorporeal photopheresis (ECP) delivery system, is approved for use in multiple countries to treat immune-related diseases.
CVC, with its expertise in healthcare, intends to invest in Therakos' research, development, and geographic expansion. The transaction is expected to close in Q4 2024, subject to regulatory approvals. Key Therakos employees will transition with the business to ensure continuity in product support and stakeholder relations.
Mallinckrodt plc, a global specialty pharmaceutical company, has announced it will report its second quarter 2024 earnings results on Tuesday, August 6, 2024. The results will cover the period ended June 28, 2024. A conference call for investors is scheduled for 8:30 a.m. ET on the same day. Interested parties can access the call through various means, including:
- Live Call Participant Registration (with dial-in)
- Audio Only Webcast Link (live and replay)
- Mallinckrodt's investor relations website
This announcement provides investors and analysts an opportunity to prepare for the upcoming financial disclosure and engage with the company's management team regarding its performance and outlook.
Mallinckrodt announced data on TERLIVAZ® (terlipressin) at the 2024 European Association for the Study of the Liver (EASL) Congress. Three posters were presented, focusing on outcomes in patients with hepatorenal syndrome (HRS) and rapid kidney function decline.
Key findings include potential benefits of early diagnosis and treatment with TERLIVAZ, resulting in 3,040 more HRS reversals, 960 fewer needing renal replacement therapy, and significant healthcare cost savings. Data also showed improved survival rates in patients with lower baseline mean arterial pressure and better renal function among those with alcohol-associated hepatitis and acute-on-chronic liver failure grades 0–2.
However, the FDA has not evaluated the safety and efficacy of TERLIVAZ within these subgroups. Limitations include small sample sizes and potential methodological errors. TERLIVAZ remains the only FDA-approved treatment for adults with HRS with rapid kidney function decline, but it poses serious respiratory risks, particularly in specific patient groups.
Mallinckrodt presented data on TERLIVAZ® (terlipressin) for treating hepatorenal syndrome (HRS) at the 2024 Digestive Disease Week in Washington, DC. The presentations included a post-hoc analysis from the Phase III CONFIRM trial and a pooled analysis of three Phase III studies. The results indicate that TERLIVAZ is effective in improving kidney function in patients with HRS-AKI, even with dose interruptions, and is particularly beneficial for patients with baseline serum creatinine (SCr) levels below 5 mg/dL. TERLIVAZ is the first FDA-approved treatment for HRS with rapid kidney function decline, impacting over 42,000 Americans annually. The safety profile includes risks of serious respiratory failure and ischemic events, and the treatment is not recommended for certain high-risk patients.
Mallinckrodt plc reported first quarter 2024 financial results with net sales of $467.8 million, showing 10.2% year-over-year growth. The company achieved a net loss of $65.4 million, reflecting a 73.8% improvement, and delivered adjusted EBITDA of $144.9 million, up by 17.3% year-over-year. Mallinckrodt also initiated the rollout of INOmax EVOLVE DS Delivery System and anticipates the launch of Acthar Gel SelfJect Injector in the third quarter of 2024.
FAQ
What is the market cap of Mallinckrodt plc (MNK)?
